ANDA 76191, held by Barr Laboratories. Fexofenadine Hydrochloride.
As of Nov 22, 2026, ANDA 76191 (Fexofenadine Hydrochloride), held by Barr Laboratories, was first approved by FDA on Aug 31, 2005, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 31, 2005 | Original application | Approved | None posted |
| Fexofenadine Hydrochloride30MG · tablet;oral | Fexofenadine Hydrochloride | Discontinued |
| Fexofenadine Hydrochloride60MG · tablet;oral | Fexofenadine Hydrochloride | Discontinued |
| Fexofenadine Hydrochloride180MG · tablet;oral | Fexofenadine Hydrochloride | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters